Low-vision rehab could improve quality of life

Article

Low-vision rehabilitation can lead to significant improvements in overall quality of life, according to study published in the April issue of Investigative Ophthalmology and Visual Science.

Low-vision rehabilitation can lead to significant improvements in overall quality of life, according to study published in the April issue of Investigative Ophthalmology and Visual Science.

Ecosse L. Lamoureux, from the University of Melbourne, Australia and colleagues conducted a study to evaluate the effectiveness of a multidisciplinary low-vision rehabilitation programme on quality of life, measured using the Impact of Vision Impairment (IVI) instrument.

A total of 124 female and 68 male (mean age, 80.3 years) first-time referrals to low-vision clinics were assessed before and after rehabilitation. Rasch analysis was used to estimate the three IVI subscales and overall values on an interval scale. Analysis of Variance between groups (ANOVA) was used to determine whether presenting visual acuity (VA) had an interaction effect with rehabilitation change. Cohen d values were used to estimate the magnitude of change and the standardized response mean (SRM) procedure was used to determine the clinical significance of such changes.

Most subjects (62%) had age-related macular degeneration (AMD) and were categorized as moderately to severely vision impaired (<6/18; 78%). Following rehabilitation, significant improvements were recorded for the overall IVI score (p=0.006) and two subscales: 'reading and accessing information' and 'emotional well-being' (p=0.007 and 0.009, respectively). However, no significant improvement was recorded for the 'mobility and independence' subscale (p=0.07). The level of post-rehabilitation improvement was found to be relatively moderate (Cohen d=0.17-0.30) and clinically modest (SRM=0.22-0.42).

The authors concluded that significant improvements in quality of life can be achieved through low-vision rehabilitation, however, the magnitude and clinical significance of rehabilitation-induced gains are modest. They suggest that further investigation in other models of rehabilitation are required to optimize the quality of life gains that could be achieved.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.